Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT01942005
NCT01942005CompletedNot Applicable

EVER/TMC Mutation as Marker of the Risk of Cutaneous Carcinoma in Immunosuppressed Patients,Especially Patients After Organ Transplantation and Patients With HIV Infection

Andreas Arnold1 site in 1 country144 target enrollmentStarted: January 2010Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
144
Locations
1
Primary Endpoint
Detection of mutation / specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen.
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Detection of mutation / specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen.

Detailed Description

correlation between possibly detected mutation/specific polymorphism and kind and number of neoplasm, age of patients, UV burden, duration and kind of immunosuppression.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •patients in an immunosuppressive condition either by immunosuppressants or by HIV infection

Exclusion Criteria

  • •written informed consent not given

Outcomes

Primary Outcomes

Detection of mutation / specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen.

Time Frame: 7 years

Secondary Outcomes

  • correlation between possibly detected mutation/specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen and a composite of kind and number of neoplasm, age of patients, UV burden, duration and kind of immunosuppression.(7 years)

Investigators

Sponsor
Andreas Arnold
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Andreas Arnold

Dr. med. Andreas Arnold, senior physician

University Hospital, Basel, Switzerland

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
New Genetic Mutations in Thromboembolic Venous Disease Idiopathic. Study "FIT GENETIQUE".Thromboembolic Venous Disease
NCT02841085University Hospital, Brest613
Completed
Not Applicable
Identification of New Genetic Markers of Risk of Venous Thromboembolism Recurrence by Analyzing Whole GenomeVenous Thromboembolism
NCT02904967Assistance Publique Hopitaux De Marseille221
Unknown
Not Applicable
Collection of Biological Data With Potential Prognostic Relevance in Patients With MYELODYSPLASTIC SYNDROMESMyelodysplastic Syndrome
NCT01291745Fondazione Amelia Scorza Onlus200
Completed
Not Applicable
Detecting EGFR T790M Mutations From Circulating Tumor CellsNon Small Cell Lung Cancer
NCT01734915Massachusetts General Hospital40
Completed
Not Applicable
Construction and External Validation of a Predictive Clinico-biological Score of the Risk of Venous Thrombosis in Women Under Combined Oral ContraceptivesVenous Thromboembolism
NCT03309293Assistance Publique Hopitaux De Marseille1,454